1 / 15

Mark Y. Chan Associate Professor Yong-Loo Lin School of Medicine Senior Consultant

Dynamic Risk Stratification in ACS. Mark Y. Chan Associate Professor Yong-Loo Lin School of Medicine Senior Consultant National University Heart Centre, Singapore. Question 1: Does a change in biomarker levels over time confer a change in prognosis in patients with ACS?.

drouse
Download Presentation

Mark Y. Chan Associate Professor Yong-Loo Lin School of Medicine Senior Consultant

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dynamic Risk Stratification in ACS Mark Y. Chan Associate Professor Yong-Loo Lin School of Medicine Senior Consultant National University Heart Centre, Singapore

  2. Question 1: Does a change in biomarker levels over time confer a change in prognosis in patients with ACS?

  3. Initial NT-proBNP and hs-CRP Re-assess NT-proBNP and hs-CRP 6 month-baseline NT-proBNP NT-proBNP NT-proBNP Mortality risk 6 month-baseline hs-CRP MI risk hs-CRP hs-CRP Hospitalization for NSTEACS Escalate or modify management? Re-measure NT-proBNP and hs-CRP? Initial treatment Baseline 6 months 30 months

  4. TRILOGY-ACS Biomarker Substudy Presented at AHA 2014

  5. Changes in NT-proBNP and hs-CRP (delta) from baseline to 6 months

  6. Adjusted hazard ratio of delta NT-proBNP

  7. Adjusted hazard ratio of delta hs-CRP for CV events

  8. Quantitative changes in risk associated with changes in biomarker levels

  9. Question 2: For expensive prognostic biomarkers like miRNA, what is the best timepoint to measure them

  10. miRNAs measured at baseline and 30 days Presented at AHA 2016

  11. Differential prediction of MI and CV death risk by miRs measured at baseline and 30 days

  12. Conclusions • An increase/decrease of NT-proBNP over time is quantitatively associated with an increase/decrease in risk of CV death • An increase/decrease of hs-CRP over time is quantitatively associated with an increased/decrease in MI risk. • miRs measured at 30-day are far greater prognostic value for recurrent ischemic events than miRs measured at baseline

  13. Prognostic biomarker studies must not only study the association between measurements at individual timepoints and events, they must also investigate the delta between timepoints • For multi-marker platforms, different markers may have differential prognostic value at different phases in the longitudinal evolution of the disease

  14. Acknowledgements • Duke Molecular Physiology Lab • Svati Shah, Lydia Kwee, Libby Grass • Duke Clinical Research Institute • Matthew Roe, Megan Neely

More Related